{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:19:36Z","timestamp":1789507176144,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.biopha.2023.114247","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T03:55:24Z","timestamp":1673841324000},"page":"114247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Computer-aided drug design for the pain-like protease (PLpro) inhibitors against SARS-CoV-2"],"prefix":"10.1016","volume":"159","author":[{"given":"Hongwei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhui","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114247_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect., Genet. Evol.: J. Mol. Epidemiol. Evolut. Genet. Infect. Dis."},{"issue":"20","key":"10.1016\/j.biopha.2023.114247_bib2","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.biopha.2023.114247_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.114247_bib4","first-page":"710","article-title":"From SARS to COVID-19: what we have learned about children infected with COVID-19","volume":"96","author":"Zhou","year":"2020","journal-title":"Int. J. Infect. Dis.: IJID: Off. Publ. Int. Soc. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2023.114247_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1213\/ANE.0000000000004845","article-title":"Coronaviruses and SARS-CoV-2: a brief overview","volume":"131","author":"Ludwig","year":"2020","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.biopha.2023.114247_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/pathogens9030240","article-title":"Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2","volume":"9","author":"Rehman","year":"2020","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.biopha.2023.114247_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/cells3020386","article-title":"The ubiquitin-conjugating system: multiple roles in viral replication and infection","volume":"3","author":"Calistri","year":"2014","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.114247_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2013.11.040","article-title":"MERS-CoV papain-like protease has deISGylating and deubiquitinating activities","volume":"450\u2013451","author":"Mielech","year":"2014","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.biopha.2023.114247_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.abb.2007.07.006","article-title":"Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease","volume":"466","author":"Lindner","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"issue":"24","key":"10.1016\/j.biopha.2023.114247_bib10","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","article-title":"The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity","volume":"79","author":"Barretto","year":"2005","journal-title":"J. Virol."},{"issue":"7798","key":"10.1016\/j.biopha.2023.114247_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114247_bib12","first-page":"243","article-title":"In silico oncology drug repositioning and polypharmacology","author":"Cheng","year":"1878","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114247_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.drudis.2016.09.019","article-title":"Design of efficient computational workflows for in silico drug repurposing","volume":"22","author":"Vanhaelen","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2023.114247_bib14","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.drudis.2015.12.007","article-title":"In silico methods to address polypharmacology: current status, applications and future perspectives","volume":"21","author":"Lavecchia","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.114247_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010611-134630","article-title":"Novel computational approaches to polypharmacology as a means to define responses to individual drugs","volume":"52","author":"Xie","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2023.114247_bib16","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.1038\/ncomms11363","article-title":"Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114247_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2023.114247_bib18","doi-asserted-by":"crossref","unstructured":"RutW., Lv Z., Zmudzinski M., et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design [J]. bioRxiv: the preprint server for biology, 2020.","DOI":"10.1101\/2020.04.29.068890"},{"issue":"5","key":"10.1016\/j.biopha.2023.114247_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.biopha.2023.114247_bib20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/bib\/bbaa382","article-title":"Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro","volume":"22","author":"Bharadwaj","year":"2021","journal-title":"Brief. Bioinforma."},{"key":"10.1016\/j.biopha.2023.114247_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cplett.2021.138463","article-title":"Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: molecular docking, DFT and MD simulation investigations","volume":"771","author":"Rasool","year":"2021","journal-title":"Chem. Phys. Lett."},{"issue":"16","key":"10.1016\/j.biopha.2023.114247_bib22","article-title":"When virtual screening yields inactive drugs: dealing with false theoretical friends","volume":"17","author":"Cer\u00f3n-Carrasco","year":"2022","journal-title":"ChemMedChem"},{"issue":"7854","key":"10.1016\/j.biopha.2023.114247_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/d41586-021-00958-4","article-title":"The race for antiviral drugs to beat COVID \u2013 and the next pandemic","volume":"592","author":"Dolgin","year":"2021","journal-title":"Nature"},{"issue":"7047","key":"10.1016\/j.biopha.2023.114247_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2023.114247_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"issue":"8","key":"10.1016\/j.biopha.2023.114247_bib26","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"18","key":"10.1016\/j.biopha.2023.114247_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2023.114247_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"issue":"7835","key":"10.1016\/j.biopha.2023.114247_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114247_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.biopha.2023.114247_bib31","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmc.2012.07.038","article-title":"Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases","volume":"20","author":"Park","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.biopha.2023.114247_bib32","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1042\/BCJ20210244","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease","volume":"478","author":"Lim","year":"2021","journal-title":"Biochem. J."},{"issue":"2\u20134","key":"10.1016\/j.biopha.2023.114247_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1025386326946","article-title":"Rational selection of training and test sets for the development of validated QSAR models","volume":"17","author":"Golbraikh","year":"2003","journal-title":"J. Comput. -Aided Mol. Des."},{"issue":"1","key":"10.1016\/j.biopha.2023.114247_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1747-0285.2012.01339.x","article-title":"Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent cathepsin D inhibitors","volume":"80","author":"Sakkiah","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.biopha.2023.114247_bib35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/CAD.0000000000000245","article-title":"Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening","volume":"26","author":"Liu","year":"2015","journal-title":"Anti-Cancer Drugs"},{"issue":"11\u201312","key":"10.1016\/j.biopha.2023.114247_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","article-title":"Pharmacophore modeling and applications in drug discovery: challenges and recent advances","volume":"15","author":"Yang","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.114247_bib37","doi-asserted-by":"crossref","unstructured":"Shoombuatong W., Prathipati P., Owasirikul W., et al. Towards the Revival of Interpretable QSAR Models [J]. 2017, 24: 3\u201355.","DOI":"10.1007\/978-3-319-56850-8_1"},{"issue":"1","key":"10.1016\/j.biopha.2023.114247_bib38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/qsar.200390007","article-title":"The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models [J]","volume":"22","author":"Tropsha","year":"2003","journal-title":"QSAR Comb. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2023.114247_bib39","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1021\/jm00090a001","article-title":"3D database searching in drug design","volume":"35","author":"Martin","year":"1992","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2023.114247_bib40","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ardp.201500045","article-title":"Generated 3D-common feature hypotheses using the HipHop method for developing new topoisomerase I inhibitors","volume":"348","author":"Ataei","year":"2015","journal-title":"Arch. der Pharm."},{"key":"10.1016\/j.biopha.2023.114247_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.compbiolchem.2018.06.005","article-title":"Docking techniques in pharmacology: How much promising?","volume":"76","author":"Gupta","year":"2018","journal-title":"Comput. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2023.114247_bib42","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1021\/acs.jcim.1c00263","article-title":"Benchmarking the ability of common docking programs to correctly reproduce and score binding modes in SARS-CoV-2 protease Mpro","volume":"61","author":"Zev","year":"2021","journal-title":"J. Chem. Inf. Model"},{"issue":"3","key":"10.1016\/j.biopha.2023.114247_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/prot.340080302","article-title":"Automated docking of substrates to proteins by simulated annealing","volume":"8","author":"Goodsell","year":"1990","journal-title":"Proteins"},{"issue":"4","key":"10.1016\/j.biopha.2023.114247_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00124499","article-title":"Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4 [J]","volume":"10","author":"Morris","year":"1996","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"16","key":"10.1016\/j.biopha.2023.114247_bib45","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2023.114247_bib46","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med Chem."},{"issue":"21","key":"10.1016\/j.biopha.2023.114247_bib47","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med Chem."},{"issue":"6","key":"10.1016\/j.biopha.2023.114247_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10822-012-9575-9","article-title":"Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide","volume":"26","author":"Repasky","year":"2012","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"16","key":"10.1016\/j.biopha.2023.114247_bib49","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"Journal of computational chemistry"},{"issue":"2","key":"10.1016\/j.biopha.2023.114247_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph Model"},{"issue":"13","key":"10.1016\/j.biopha.2023.114247_bib51","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2023.114247_bib52","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"B\u00e1ez-Santos","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7677","key":"10.1016\/j.biopha.2023.114247_bib53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.biopha.2023.114247_bib54","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2023.114247_bib55","doi-asserted-by":"crossref","first-page":"13208","DOI":"10.1038\/s41598-021-92416-4","article-title":"Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19","volume":"11","author":"Redhead","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2023.114247_bib56","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1039\/C9CP06459A","article-title":"Improving the performance of the MM\/PBSA and MM\/GBSA methods in recognizing the native structure of the Bcl-2 family using the interaction entropy method","volume":"22","author":"Zhong","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"13","key":"10.1016\/j.biopha.2023.114247_bib57","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1093\/nar\/gkz499","article-title":"Effect of mutations on binding of ligands to guanine riboswitch probed by free energy perturbation and molecular dynamics simulations","volume":"47","author":"Chen","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2023.114247_bib58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.bb.18.060189.002243","article-title":"Free energy via molecular simulation: applications to chemical and biomolecular systems","volume":"18","author":"Beveridge","year":"1989","journal-title":"Annu Rev. Biophys. Biophys. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2023.114247_bib59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/acschemneuro.7b00490","article-title":"What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation","volume":"9","author":"Xue","year":"2018","journal-title":"ACS Chem. Neurosci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:55:35Z","timestamp":1773388535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":59,"alternative-id":["S0753332223000355"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114247","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computer-aided drug design for the pain-like protease (PLpro) inhibitors against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114247"}}